Nabla Bio

Executive Summary

Nabla Bio, founded in 2020 in Boston, is pioneering a design-driven approach to biologic drug development by integrating generative AI with high-throughput, human-relevant experimentation. The company aims to bypass traditional trial-and-error methods by engineering antibodies and multispecifics with predefined properties from the outset, potentially shortening development timelines and improving drug safety and efficacy. Its platform combines de novo design with large-scale wet-lab validation, targeting a broad range of therapeutic areas. As a privately held company, Nabla Bio has not disclosed funding or valuation details, but its technology positions it in the competitive AI-enabled drug discovery space. The firm's early-stage status implies near-term catalysts will likely involve proof-of-concept data or strategic collaborations to validate its platform. If successful, Nabla Bio could become a key player in the biologics design field, though significant execution and validation risks remain.

Upcoming Catalysts (preview)

• Q2 2026Series B Funding Announcement70% success
• Q4 2026Pharmaceutical Partnership or License Deal50% success
• Q3 2026Preclinical Proof-of-Concept Data Release60% success